InsidersTradesSigma
Edgewise Therapeutics, Inc. Stock: price and directors' dealings · United States · SEC (Form 4)
Follow the Edgewise Therapeutics, Inc. stock price and the full management transaction log of the company, a listed equity based in United States. Shares trade on US US, under the oversight of SEC (Form 4). Operating in the Healthcare & Pharma sector, Edgewise Therapeutics, Inc. has published 86 public disclosures. Market capitalisation: €3.7bn. The latest transaction was reported on 7 May 2025 (Levée d'options). Among the most active insiders: Russell Alan J. Every trade is free.
86
Insider Decl.
0
Thresholds
€40m
10 ops.
Buy Volume
€4m
24 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Edgewise Therapeutics, Inc. Buy (bullish), based on 12 analysts. Average price target: US$46.08.
45Σ signal
Informational score on this market. Our backtest validates the signal only on 8 EU venues; elsewhere (notably US markets) insider buys historically invert or do not hold. Not a recommendation.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
Last declaration on 7 May 2025
Declarations86 total
5,209 shares0Common StockSEC:0001562180-25-003656:0
5,209 shares0Common StockSEC:0001562180-25-003660:0
5,209 shares0Common StockSEC:0001562180-25-003655:0
10,417 shares0Common StockSEC:0001562180-25-003658:0
10,417 shares0Common StockSEC:0001562180-25-003657:0
5,209 shares0Common StockSEC:0001562180-25-003659:0
372,578 shares@ US$20.1339.2% of flowCommon StockSEC:0000947871-25-000359:0
Ideal exit: 29 Dec 2025 (T+270)
372,578 shares@ US$20.1339.2% of flowCommon StockSEC:0000947871-25-000360:0
Ideal exit: 29 Dec 2025 (T+270)
559 shares0Common StockSEC:0001562180-25-002992:0
100 shares@ US$0.181.1% of flowCommon StockSEC:0001562180-25-002293:0
200 shares@ US$0.180.0% of flowCommon StockSEC:0001562180-25-002294:0
8,636 shares@ US$0.1898.9% of flowCommon StockSEC:0001562180-25-001025:0
8,015 shares@ US$0.180.0% of flowCommon StockSEC:0001562180-25-001026:0
10,000 shares@ US$1.9320.1% of flowCommon StockSEC:0001562180-25-001024:0
25,000 shares@ US$7.0848.3% of flowCommon StockSEC:0001562180-25-000697:0
100,000 shares@ US$0.180.5% of flowCommon StockSEC:0001562180-24-008663:0
29,709 shares@ US$8.94100.0% of flowCommon StockSEC:0001562180-24-008599:0
70,000 shares@ US$0.7115.3% of flowCommon StockSEC:0001562180-24-007353:0
50,000 shares@ US$0.719.5% of flowCommon StockSEC:0001562180-24-006946:0
75,000 shares@ US$0.180.3% of flowCommon StockSEC:0001562180-24-006947:0
42,068 shares@ US$1.9378.7% of flowCommon StockSEC:0001562180-24-006943:0
46,068 shares@ US$1.9326.8% of flowCommon StockSEC:0001562180-24-006942:0
7,162 shares@ US$28.288651.7% of flowCommon StockSEC:0001562180-24-006945:0
5,208 shares0Common StockSEC:0001562180-24-003830:0
10,417 shares0Common StockSEC:0001562180-24-003826:0
25 of 86 declarations
About Edgewise Therapeutics, Inc.
Recent highlights include Edgewise’s early-May 2026 first-quarter financial update and clinical progress report in muscular dystrophy and cardiovascular programs. The company also outlined 2026 corporate priorities and announced participation in a RBC Capital Markets healthcare conference in May 2026. In the context of SEC Form 4 insider filings, investors should interpret insider transactions carefully, as they often reflect equity compensation or prearranged 10b5-1 plans rather than a standalone fundamental signal. Overall, Edgewise remains a specialty biotech name with meaningful scientific optionality, but also a high-risk profile typical of clinical-stage companies.
